<!DOCTYPE html>
<html lang="en">
  <head>
    <meta charset="UTF-8" />
    <meta http-equiv="X-UA-Compatible" content="IE=edge" />
    <meta name="viewport" content="width=device-width, initial-scale=1.0" />
    <title>Balancing Survival and Treatment in Metastatic NSCLC - The challenges of systemic toxicities </title>
    <meta name="description" content="Explore the challenges of extending survival without increasing systemic treatment toxicities in metastatic non-small cell lung cancer (NSCLC). Understand the impact of current therapies on patient well-being, physical functioning, and overall survival rates.">
    
    <link rel="stylesheet" href="./styles.css" />
    <style>
      @import url("https://use.typekit.net/cru6gsk.css");
    </style>
  </head>
  <body>
    <div class="container">
      <section id="header">
        <img
          class="img logo "
          src="./assets/Novocure_Logo.svg"
          alt="Novocure Logo"
        />
      
      </section>
      <section id="heroContent">
        <video autoplay muted loop id="heroVideo" class="desktop">
          <source src="./assets/v3_unmetneeds-lung-slide-eng-d-1440-900.mp4" type="video/mp4">
          Your browser does not support the video tag.
      </video>

      <img src="./assets/v3_unmetneeds-lung-slide-eng-m-480x480.gif" type="gif" id="heroGif" class="mobile" style="display: none;">

      
        <div class="heroContainerForCopy">
          <!-- <img
          class="img logo mobile"
          src="./assets/Lungs-Mobile.svg"
          alt="Novocure Logo"
          style="display: none;    width: 100vw;margin-left: -20px;margin-right: 0px;max-width: 105%;  margin-bottom: -55px;  margin-top: -40px;"
        /> -->
          <p class="headerTopCopy">
            In the treatment of metastatic non&#8209small cell lung cancer (NSCLC),
          </p>
          <div class="shortLine"></div>
          <h1 class="headerMainCopy">
            What's <br class="mobile" style="display: none;"> keeping <br class="mobile" style="display: none;"> survival out  <br > of balance<span style="font-family: 'din-2014';">?</span>
          </h1>
          <p class="headerTopCopy headerBottomCopy">
            Despite therapeutic advances,  <br class="mobile" style="display: none;">oncologists continue to face the
            <br class="mobile" style="display: none;">imbalance between additional toxicities from systemic treatments and extended survival in patients with metastatic NSCLC.<sup>1,2,</sup>*
          </p>
        </div>
        <div class="CTAContainer">
          <div class="heroContentCTAContainer">
            <div class="headerTopCopy CTALeftCopy">
              <b>Stay in touch</b> to learn more about what needs to change.
            </div>
            <button class="CTASignup CTABtn">
              <p style="color: black">
                Sign Up
                <svg
                  style="margin-left: 14px"
                  xmlns="http://www.w3.org/2000/svg"
                  width="7"
                  height="10"
                  viewBox="0 0 7 10"
                  fill="none"
                >
                  <path
                    d="M1.5 9L5.5 5L1.5 1"
                    stroke="#000525"
                    stroke-width="2"
                    stroke-linecap="round"
                    stroke-linejoin="round"
                  />
                </svg>
              </p>
            </button>
          </div>
        </div>
      </section>

      <section class="bodyContentSectionContainer customContainerPadding">
        <h2 class="sectionHeader">
          As metastatic NSCLC progresses, there remains a gap in the ability to
          extend survival without adding systemic treatment toxicities
        </h2>
        <div class="mediaOSContentContainer">
          <div class="medianOSLeftContainer">
            <img src="./assets/MedianOSLeft_v3.svg" class="desktop"/>
            <img src="./assets/MedianOS-Mobile_v2.svg" class="mobile" style="display: none"/>
          </div>
          <div class="medianOSRightContainer">
            The efficacy of chemotherapy following the first-line combination of
            immunotherapy and chemotherapy is modest and involves additional
            systemic toxicities that patients struggle to endure.<sup>1,3</sup>
          </div>
        </div>
      </section>
      <div class="gradientContainer">
      <section class="bodyContentSectionContainer pb-90">
        <h2 class="sectionHeader pt-15">Consequences for patients</h2>
        <p class="whiteBodyCopy pb-50">
          Treatment options for metastatic NSCLC are currently limited to biochemical
          systemic modalities that may result in limited median overall
          survival, especially in later lines of treatment.<sup>3,4</sup>
        </p>
        <img src="./assets/5-year-survival-graphic_v3.svg" class="desktop" />
        <img
          src="./assets/5-year-survival-graphic-mobile_v3.svg"
          class="mobile ml-0-mobile"
          style="display: none;    margin-left: 10px;"
        />

        <p class="whiteBodyCopy bold treatmentCopy pt-70">
          Treatment choice may be complicated by:
        </p>
        <div class="treatmentChoiceContainer">
          <div class="shortRedLine"></div>
          <p class="whiteBodyCopy treatmentCopy pt-10">
            The burden of toxicities from current systemic therapies<sup
              >6,7</sup
            >
          </p>
          <div class="shortRedLine"></div>
          <p class="whiteBodyCopy treatmentCopy pt-10">
            Patient's age and fitness for the continuation of treatment<sup
              >8,9</sup
            >
          </p>
          <div class="shortRedLine"></div>
        </div>
      </section>
      <section class="bodyContentSectionContainer pb-75 ">
        <div class="fiftyPercContainer pt-25">
          <img src="./assets/fiftyPerc_v2.svg" class="desktop"/>
          <img src="./assets/fifty-perc-mobile.svg" class="mobile" style="display: none"/>
          
          <p class="whiteBodyCopy pl-50 widthAuto customPadding">
            <b>Approximately half</b> of patients treated for metastatic NSCLC experience
            a decline in physical functioning, which interferes with daily
            activities and overall well-being.<sup>10,§</sup>
          </p>
        </div>
        <div class="ageFitnessContainer">
          <img src="./assets/ageFtiness_v3.svg" class="desktop"/>
          <img src="./assets/ageFitnessMobile_v2.svg" class="mobile" style="display: none;"/>
        </div>

        <div class="fiftyPercContainer mobileCrossCircle">
          <img style="    scale: 1.05;
          position: relative;
          left: 7px;" src="./assets/crossCircle.svg" class="desktop"/>
          <img src="./assets/crossCircleMobile.svg" class="mobile customMobileMargin" style="display: none;"/>
          <p class="whiteBodyCopy pl-50 widthAuto customPadding">
            Moreover, studies in NSCLC that measure impact of chemotherapy
            regimens on tolerability and quality of life typically do not
            include toxicity-related patient discontinuation rates, which may
            exceed 30% among patients who receive combination therapies.<sup
              >12,13</sup
            >
          </p>
        </div>
      </section>
</div>
      <section class="novelModality">
        <div class="novelModalityContentContainer">
          <img
          class="img logo mobile lungsMobile"
          src="./assets/v2-lungs-mobile.png"
          alt="Novocure Logo"
          style="display: none;    width: 100vw;
          margin-left: -20px;
          margin-right: 0px;
          max-width: 105%;"
        />
          <p class="novelModalityCopy">
            <span>We need to consider</span><br /><br class="mobile" style="display: none;">
            novel modalities that target tumor behaviors in innovative ways in
            order to extend survival without added systemic toxicities
          </p>
        </div>
      </section>

      <section class="signUpContainer pb-90">

        <div class="thankyou" style="display:none;">
          <h2 class="signUpHeader">THANK YOU </h2>
          <p class="whiteBodyCopy" style="PADDING-BOTTOM:0px;">
            Thank you for registering with ImbalanceinNSCLC.com
          </p>
          <p class="whiteBodyCopy">
            Look for email updates and information soon.
          </p>
        </div>
        <div class="signUpContent">
          <h2 class="signUpHeader">Sign up for updates and information</h2>
        </div>
        <div class="signUpForm"  id="signupForm">
          <p class="requiredFieldNotice">*Indicates required field.</p>
          <form action="#" method="post">
            <label for="firstName">First name<span style="color:#ff005a">*</span></label>
            <input type="text" id="firstName" name="firstName" />

            <label for="lastName">Last name<span style="color:#ff005a">*</span></label>
            <input type="text" id="lastName" name="lastName" />

            <label for="emailAddress">Email address<span style="color:#ff005a">*</span></label>
            <input
              type="email"
              id="emailAddress"
              name="emailAddress"
              required
            />

            <label for="confirmEmail">Confirm email address<span style="color:#ff005a">*</span></label>
            <input
              type="email"
              id="confirmEmail"
              name="confirmEmail"
              required
            />

            <label for="specialty">Specialty<span style="color:#ff005a">*</span></label>
            <input type="text" id="specialty" name="specialty" required />
    
            <label id="npiLabel" for="npiNumber">NPI/License number<span style="color:#ff005a">*</span></label>
            <div class="npi-container">
                <input type="text" id="npiNumber" name="npiNumber" required />
            
                <span class="npi-info-icon">
                  <svg width="24" height="24" viewBox="0 0 24 24" fill="none" xmlns="http://www.w3.org/2000/svg">
                    <circle cx="12" cy="12" r="11.5" stroke="white"/>
                    <text x="11" y="16" font-family="Arial, sans-serif" font-size="12px" fill="white">i</text>
                </svg>
                
                </span>
                <div class="npi-hover-modal">
                    <span style="color: white;">Use this link <a href="https://npiregistry.cms.hhs.gov/" style="text-decoration: underline;color: white;" target="_blank" >https://npiregistry.cms.hhs.gov/</a> to look up your NPI number.</span>
                </div>
            </div>
    
            <label for="institutionName">Institution name</label>
            <input type="text" id="institutionName" name="institutionName" />
    
            <label for="institutionAddress">Institution address</label>
            <input type="text" id="institutionAddress" name="institutionAddress" />

            <div class="checkboxContainer">
              <input type="checkbox" id="agree" name="agree" />
              <label for="agree"
                >By clicking here, I am agreeing to the statements below and
                confirm that I have read and accept <a target="_blank"  href="
                https://www.novocure.com/novocure-website-privacy-notice/" style="text-decoration: underline;color: white;">Novocure's Privacy Policy</a>. I
                also affirm that I am at least eighteen (18) years of age or
                older. I authorize Novocure Inc. (Novocure), its affiliates and
                companies working with Novocure to contact me by direct mail,
                email, telephone and electronic message (including autodialed
                and pre-recorded calls and messages) for marketing purposes,
                such as: to keep me informed about company news, products and
                patient support services; to provide me special offers regarding
                Novocure products and programs; to conduct market research or
                surveys; or other opportunities that may be of interest to me. I
                further understand that the information that I share with
                Novocure may be used by Novocure, its affiliates, and companies
                working with Novocure to develop future products, services, and
                programs. I understand that I may choose to no longer receive
                further communications from Novocure by following the
                unsubscribe instructions on the communication.<span style="color:#ff005a">*</span></label
              >
            </div>

            <button id="formBtn" type="submit" class="signUpButton">
              <span class="signUpBtnTxt">SIGN UP</span>
              <img src="./assets/signUpArrow_larger.svg " />
            </button>
          </form>
        </div>
      </section>

      <section class="footerContainer">
        <div class="footnotes">
          <p data-symbol="*">
            NSCLC, non-small cell lung cancer.
          </p>
          <p data-symbol="†"> 
            OS, overall survival.
          </p>
          <p data-symbol="‡">
            Based on a multicenter retrospective study evaluating the efficacy
            of second-line chemotherapies after progression following first-line
            chemo‑immunotherapy in 124 patients with metastatic NSCLC (mean age
            63).<sup>3</sup>
          </p>
          <p data-symbol="§">
            Chemotherapy and immunotherapy combinations in adults with NSCLC
            (≥65 years of age).<sup>10</sup>
          </p>
          <p data-symbol="||">
            ECOG, Eastern Cooperative Oncology Group. 
          </p>
        </div>
        <div class="references">
          <b>References:</b> <b>1.</b> Ramirez RA, Lu J, Thomas KEH. Quality of life for
          non-small cell lung cancer patients in the age of immunotherapy.
          <i>Transl Lung Cancer Res</i>. 2018;7(Suppl 2):S149-S152.
          doi:10.21037/tlcr.2018.03.10 <b>2.</b> Suresh K, Naidoo J, Lin CT, Danoff S.
          Immune checkpoint immunotherapy for non-small cell lung cancer:
          benefits and pulmonary toxicities. <i>Chest.</i> 2018;154(6):1416-1423.
          doi:10.1016/j.chest.2018.08.1048 <b>3.</b> Auclin E, Benitez-Montanez J,
          Tagliamento M, et al. Second-line treatment outcomes after progression
          from first-line chemotherapy plus immunotherapy in patients with
          advanced non-small cell lung cancer. <i>Lung Cancer</i>. 2023;178:116-122.
          doi:10.1016/j.lungcan.2023.02.002 <b>4.</b> Garon EB, Ciuleanu T-E, Arrieta
          O, et al. Ramucirumab plus docetaxel versus placebo plus docetaxel for
          second-line treatment of stage IV non-small-cell lung cancer after
          disease progression on platinum-based therapy (REVEL): a multicentre,
          double-blind, randomised phase 3 trial. <i>Lancet</i>.
          2014;384(9944):665-673. doi:10.1016/S0140-6736(14)60845-X <b>5.</b> American
          Society of Clinical Oncology (ASCO). Lung cancer – Non-small cell:
          statistics. Cancer.Net. Accessed September 12, 2023.
          https://www.cancer.net/cancer-types/lung-cancer-non-small-cell/statistics#:~:text=For
          <b>6.</b> Sjøgren K, Jacobsen KA, Grønberg BH, Halvorsen TO. Timing of severe
          toxicity from chemotherapy in patients with lung cancer. <i>Anticancer
          Res.</i> 2020;40(11):6399-6406. doi:10.21873/anticanres.14661 <b>7.</b> Yang F,
          Shay C, Abousaud M, et al. Patterns of toxicity burden for
          FDA‑approved immune checkpoint inhibitors in the United States. <i>J Exp
          Clin Cancer Res</i>. 2023;42(4):1-21. doi:10.1186/s13046-022-02568‑y <b>8.</b>
          Kim J, Hurria A. Determining chemotherapy tolerance in older patients
          with cancer. <i>J Natl Compr Canc Netw</i>. 2013;11(12):1494-1502.
          doi:10.6004/jnccn.2013.0176 <b>9.</b> West H, Jin JO. Performance status in
          patients with cancer. <i>JAMA Oncol.</i> 2015;1(7):998.
          doi:10.1001/jamaoncol.2015.3113 <b>10.</b> Singhal S, Walter LC, Smith AK, et
          al. Change in four measures of physical function among older adults
          during lung cancer treatment: a mixed methods cohort study. <i>J Geriatr
          Oncol.</i> 2023;14(2):101366. doi:10.1016/j.jgo.2022.08.015 <b>11.</b> Sehgal K,
          Gill RR, Widick P, et al. Association of performance status with
          survival in patients with advanced non-small cell lung cancer treated
          with pembrolizumab monotherapy. <i>JAMA Netw Open.</i> 2021;4(2):e2037120.
          doi:10.1001/jamanetworkopen.2020.37120 <b>12.</b> Alexa T, Lavinia A, Luca A, Miron L, Alexa ID. Incidence of chemotherapy discontinuation and characteristics of elderly patients with non-small cell lung cancer treated with platinum-based doublets. <i>Contemp Oncol (Pozn)</i>. 2014;18(5):340-3. doi:10.5114/wo.2014.45293  <b>13.</b> Gridelli C, Gallo C,
          Shepherd FA, et al. Gemcitabine plus vinorelbine compared with
          cisplatin plus vinorelbine or cisplatin plus gemcitabine for advanced
          non–small-cell lung cancer: a phase III trial of the Italian GEMVIN
          Investigators and the National Cancer Institute of Canada Clinical
          Trials Group. <i>J Clin Oncol</i>. 2003;21(16):3025-3034.
          doi:10.1200/JCO.2003.06.099
        </div>
        <div class="bottomFooter">
          <img src="./assets/Novocure_Logo.svg" />
          <p class="bottomCopy"><span style="font-size: 11px;
            position: relative;
            top: -2px;">©</span>2023 Novocure GmbH. All Rights Reserved. Novocure is a registered trademark of Novocure GmbH. GLB-NOV-0082 v1.0 December 2023</p> 
          </div>
      </section>
    </div>
    <script src="./index.js"></script>
    <script>
      document.querySelector('.CTASignup').addEventListener('click', function() {
        document.getElementById('signupForm').scrollIntoView({ behavior: 'smooth' });
      });
    </script>
  </body>
</html>
